Novartis says Alcon glaucoma treatment approved in EU
ZURICH (Reuters) - Swiss pharmaceutical group Novartis said the European Commission has approved its eyecare unit Alcon's Simbrinza treatment for glaucoma, a chronic, sight-threatening eye disease.
Alcon said in a statement on Monday the Simbrinza eye drops suspension had been approved to decrease elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
"We are pleased to introduce the only fixed combination therapy without a beta-blocker to help more glaucoma patients manage their progressive eye condition," Jeff George, global head of Alcon, said in the statement.
(Reporting by Silke Koltrowitz; Editing by Kenneth Maxwell)
- Alabama man gets $1,000 in police settlement, his lawyers get $459,000
- Man arrested after jumping White House fence, causing lockdown
- Probe: Athletes took fake classes at University of North Carolina
- Attack on parliament, killing of soldier stun Canada's capital |
- A Minute With: Shailene Woodley on teen sex, violence and Marvel